Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo International agrees to buy Dava Pharma for $575m
The purchase price of Dava is $575m in cash, with additional consideration of about $25m contingent on the achievement of certain sales milestones. The acquisition would improve Endo’s
The purchase price of Dava is $575m in cash, with additional consideration of about $25m contingent on the achievement of certain sales milestones. The acquisition would improve Endo’s
The company said that the patent has broad coverage and protects development of any apoptosis-inducing ICAM-1 antibody. BioInvent chief scientific officer Björn Frendéus said the company is happy
As part of the option deal, Aurigene will receive an upfront payment from Orion, followed by a licensing fee, milestones and royalties upon exercising the option at the
According to the company, early launch of these products was fueled by the strong feedback from many national retailers in the US. The company has been working with
Ligand’s IRAK4 is a major signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with
As part of the deal, Abbott will acquire Garden Hills, which currently owns more than 80% of Veropharm, for about $395m or $495m, depending on Garden Hills’ share
The company said that BNC375 and related compounds have displayed potent efficacy in animal cognitive impairment models. As part of the deal, Merck will provide funding for all
ILUVIEN (190 micrograms intravitreal implant in applicator) has been designated a C Class product in Italy and it will be available initially to private paying patients. The company
The EMA orphan drug status provides a number of benefits, including ten years of market exclusivity from product launch in the EU, fee reductions, and access to the
Dimension Therapeutics is focused on developing new adeno-associated virus (AAV) gene therapy treatments for rare diseases. Bayer HealthCare member of the Executive Committee and head of Global Drug